Needham, MA 02494 (617) 916-5445 (Address, including zip code and telephone number, including area code, of registrant’s principal executive offices) Paul Peter Tak M.D., Ph.D., FMedSci . ADVANTAGENE, INC. Nov 2016 – Present4 years 1 month. Biliary Tract Cancers (BTC) Market Size Anticipated to Soar During the Forecast Period 2021-30 at a CAGR of 11.69% in the 7MM, Projects DelveInsight PR Newswire LAS VEGAS, May 3, … Advantagene, Inc. d.b.a. Candel Therapeutics is developing proprietary immuno-oncology platforms, including its Gene Mediated Cytotoxic Immunotherapy (GMCI) and the oncolytic rQNestin34.5 platforms for the treatment of solid tumors. Location: Greater San Diego Area, CA ... biopharmaceutical manufacturing and bio-processing equipment design and manufacturing to Advantagene. Amended and Restated Employment Agreement by and between Advantagene Amended and Restated Employment Agreement by and between Advantagene, Inc. and Estuardo Aguilar-Cordova dated November 13, 2018 Contract Categories: Human Resources - Employment Agreements Last year, Candel Therapeutics (Advantagene) announced that it has completed the enrollment of … Director, Information Technology. Join to Connect ... CEO at Advantagene Boston, MA. Emerging Company Profile Companies Candel Therapeutics. Presently, Alan sits on the Scientific Advisory Boards of Pharnext, a genomics company in Paris, France and he is on the Board of Directors of Candel Therapeutics (formerly Advantagene), an immune-oncology company in Needham MA. Location: Greater Boston Area, MA. The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. About Candel Therapeutics. Emerging Company Profile: Candel Therapeutics, formerly known as Advantagene, has hired a new leadership team and is aiming for a Phase III data read-out in prostate cancer in 2023. Updates: On April 1, Advantagene (doing business as Candel Therapeutics) closed on a $22.5 million Series C preferred stock financing led by Northpond Ventures. Ms. Poole joins Candel with over 25 years of global biopharmaceutical drug development and manufacturing operations experience at both established pharmaceutical and emerging biotechnology companies. It develops Gene Mediated Cytotoxic Immunotherapy (GMCI), a platform technology designed to stimulate a patient’s immune system to naturally fight against cancer. About. Nov 2016 – Present4 years 1 month. Dr. Guzik brings both a scientific and business background to his role. Last year, Candel Therapeutics (Advantagene) announced that it has completed the enrollment of … Emerging Company Profile: Candel Therapeutics, formerly known as Advantagene, has hired a new leadership team and is aiming for a Phase III data read-out in prostate cancer in 2023. Candel Therapeutics. Last year, Candel Therapeutics (Advantagene) announced that it has completed the enrollment of … Add to My Lists. Cell Therapies Pty … Catalent Inc. WARRANT TO PURCHASE COMMON STOCK filed by Candel Therapeutics, Inc. on July 16th, 2021 Candel Therapeutics is developing proprietary immuno-oncology platforms, including its Gene Mediated Cytotoxic Immunotherapy (GMCI™) and the oncolytic rQNestin34.5 platforms for the treatment of solid tumors. The treatment is done together with standard radiation therapy. Emerging Company Profile: Candel Therapeutics, formerly known as Advantagene, has hired a new leadership team and is aiming for a Phase III data read-out in prostate cancer in 2023. Advantagene Inc. Advaxis Inc. Candel Therapeutics, formerly Advantagene Inc.,is a Boston-area privately held biopharmaceutical company focused on preventing the recurrence and progression of … Candel Therapeutics USA Private Advantagene, Inc. d.b.a. Catalent Inc. and the oncolytic rQNestin34.5 platforms … We are committed to extending and improving the lives of cancer patients through the development of innovative cancer immunotherapies. Candel's most advanced candidate, CAN-2409, is an off-the-shelf adenovirus product candidate combined with the prodrug valacyclovir. Advantagene, d.b.a. Justia Forms Business Contracts Candel Therapeutics, Inc. Candel Therapeutics is a Needham, Massachusetts based biotechnology company developing its proprietary immuno-oncology platforms, including its Gene Mediated Cytotoxic Immunotherapy (GMCI™) and proprietary HSV based platform, for the treatment of solid tumors and associated neurological pathologies. Last year, Candel Therapeutics (Advantagene) announced that it has completed the enrollment of … Advantagene, Inc. d.b.a. to develop effective and safe treatments for cancer. Cell Therapies Pty … Director, Business Development and Scientist at Candel Therapeutics. Developer of oncolytic viral immunotherapy intended to empower patient's immune system to fight disease. Following the combination of our predecessor company, Advantagene, Inc., with the HSV discovery platform assets acquired from Periphagen, Inc. (Periphagen), a company focused on engineering HSV as a gene therapy vector, we formally changed our name to Candel Therapeutics, Inc. in December 2020. Advantagene (d.b.a. Candela is a unit of light. Embed. The following represents disclosure information provided by authors of this abstract. The phrase “Void After November 13, 2023” on the face of each Warrant is hereby amended to read as follows: “Void After November 13, 2025”. EMPLOYMENT AGREEMENT This Employment Agreement (“ Agreement ”) is made between Advantagene, Inc., a Delaware corporation d/b/a Candel Therapeutics (the “ Company ”), and Paul Peter Tak, M.D. Sandra Poole is Chief Operating Officer at Candel Therapeutics. Show more Show less. Vice President, Manufacturing at Candel Therapeutics. Dialing-Up The Immune System. Emerging Company Profile: Candel Therapeutics, formerly known as Advantagene, has hired a new leadership team and is aiming for a Phase III data read-out in prostate cancer in 2023. About Candel Therapeutics. Private Company. Advent Srl. The treatment is done together with standard radiation therapy. Justia Forms Business Contracts Candel Therapeutics, Inc. See what employees say it's like to work at Candel Therapeutics. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. Previously known as Advantagene, Inc., Candel Therapeutics applies biotechnology advancements to develop drugs that … Last year, Candel Therapeutics (Advantagene) announced that it has completed the enrollment of the "ULYSSES" trial, a Phase II study of ProstAtak for prostate cancer patients choosing Active Surveillance (PrTK04- NCT02768363). This report examines the approvals and manufacturing outlook for three drug molecule types that all require viral vectors in their production: gene therapies, gene-modified cell therapies, and recombinant vector … Last year, Candel Therapeutics (Advantagene) announced that it has completed the enrollment of … Previously known as Advantagene, Candel Therapeutics is working on cancer-killing viruses designed to “light up” and destroy solid tumors while triggering a long-term systemic immune response to keep cancer in remission. Emerging Company Profile: Candel Therapeutics, formerly known as Advantagene, has hired a new leadership team and is aiming for a Phase III data read-out in prostate cancer in 2023. Candel Therapeutics is developing proprietary immuno-oncology platforms, including its Gene Mediated Cytotoxic Immunotherapy (GMCI?) Advantagene, d.b.a. USA. All references to “Advantagene, Inc.” in the Warrants are hereby amended to read as follows: “Candel Therapeutics, Inc. (f/k/a Advantagene, Inc.)”. Candel Therapeutics, Inc. ClinicalTrials.gov Identifier: NCT01436968 Other Study ID Numbers: PrTK03 : First Posted: September 20, 2011 Key Record Dates: Last Update Posted: July 9, 2021 Last Verified: July 2021 . The treatment is done together with standard radiation therapy. Last year, Candel Therapeutics (Advantagene) announced that it has completed the enrollment of the "ULYSSES" trial, a Phase II study of ProstAtak for prostate cancer patients choosing Active Surveillance (PrTK04- NCT02768363). Operating Status Active. Mr. Rocamboli has been a member of the board of directors of numerous public and private companies and is currently a member of the board of directors of Cortice BioSciences (New York, NY) and Androvia Life Sciences (New York, NY) and was a member of the board of directors of Foresight Therapeutics until its sale to Shire Pharmaceuticals in 2015. Cell and Gene Therapy Catapult. Exclusive Patent License Agreement by and between Advantagene Exclusive Patent License Agreement by and between Advantagene, Inc. and The Brigham and Womens Hospital, Inc. dated September 15, 2020 Contract Categories: Intellectual Property - License Agreements Last year, Candel Therapeutics (Advantagene) announced that it has completed the enrollment of the "ULYSSES" trial, a Phase II study of ProstAtak for prostate cancer patients choosing Active Surveillance (PrTK04-NCT02768363). Advantagene, Inc. d.b.a. Advantagene Inc Advaxis Inc Advent Srl AGC Biologics SpA Ajinomoto Bio-Pharma Services ... Candel Therapeutics Catalent Inc Cell and Gene Therapy Catapult Cell Therapies Pty Ltd Embed. Needham, Massachusetts, United States. Last year, Candel Therapeutics (Advantagene) announced that it has completed the enrollment of … Candel Therapeutics, is a Needham, Massachusetts based biotechnology company developing its … Advantagene, Inc. d.b.a. We calibrate our approaches. Last year, Candel Therapeutics (Advantagene) announced that it has completed the enrollment of the "ULYSSES" trial, a Phase II study of ProstAtak for prostate cancer patients choosing Active Surveillance (PrTK04- NCT02768363). The following represents disclosure information provided by authors of this abstract. Legal Name Advantagene, Inc. Company Type For Profit. ADVANTAGENE, INC. Advantagene, Inc. d.b.a. Embed. 110 likes. By using this site, you agree that … For the biopharma industry investment, business development and competitive intelligence professionals who require information to support financing, partnering and licensing activities, BCIQ provides accurate information and context to support profitable and strategic decision making. 3. Candel Therapeutics. Prostate Cancer Market. Candel Therapeutics is a Massachusetts based biotechnology company developing its proprietary immuno-oncology platforms, including its Gene … Gene-mediated cytotoxic immunotherapy (GMCI) is an immuno-oncology approach involving local delivery of a replication-deficient adenovirus expressing herpes simplex thymidine kinase (AdV-tk) followed by anti-herpetic prodrug activation that promotes immunogenic tumor … May 26, 2016. Candel Therapeutics is developing proprietary immuno-oncology platforms, including its Gene Mediated Cytotoxic Immunotherapy (GMCI™) and the oncolytic rQNestin34.5 platforms for the treatment of solid tumors. Emerging Company Profile: Candel Therapeutics, formerly known as Advantagene, has hired a new leadership team and is aiming for a Phase III data read-out in prostate cancer in 2023. Candel Therapeutics, a company developing proprietary immuno-oncology platforms, closed a $22.5m Series C financing Frequently Asked Questions For Institutional Investors Prostate Cancer Market. About Candel Therapeutics. Previously known as Advantagene, Candel Therapeutics is working on cancer-killing viruses designed to “light up” and destroy solid tumors while … The treatment is done together with standard radiation therapy. Director, Business Development and Scientist at Candel Therapeutics. and the oncolytic rQNestin34.5 platforms for the treatment of solid tumors. The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Brian Guzik. Add to My Lists. Advantagene, Inc. d.b.a. Candel Therapeutics (also known as Advantagene) is a biopharmaceutical company developing cancer immunotherapies. Updates: On April 1, Advantagene (doing business as Candel Therapeutics) closed on a $22.5 million Series C preferred stock financing led by Northpond Ventures. Brian Guzik. USA. Candel Therapeutics is developing proprietary immuno-oncology platforms, including its Gene Mediated Cytotoxic Immunotherapy (GMCI?) Brianne Caruso. Founded date unknown. Candel develops cancer immunotherapies designed to improve the lives of cancer patients and their families. Mr. Rocamboli has been a member of the board of directors of numerous public and private companies and is currently a member of the board of directors of Cortice BioSciences (New York, NY) and Androvia Life Sciences (New York, NY) and was a member of the board of directors of Foresight Therapeutics until its sale to Shire Pharmaceuticals in 2015. Biliary Tract Cancers (BTC) Market Size Anticipated to Soar During the Forecast Period 2021-30 at a CAGR of 11.69% in the 7MM, Projects DelveInsight The treatment is done together with standard radiation therapy. Needham, Massachusetts, United States. Last year, Candel Therapeutics (Advantagene) announced that it has completed the enrollment of … Candel Therapeutics is developing proprietary immuno-oncology platforms, including its Gene Mediated Cytotoxic Immunotherapy (GMCI) and the oncolytic rQNestin34.5 platforms for the treatment of solid tumors. and the oncolytic rQNestin34.5 platforms for the treatment of solid tumors." ADVANTAGENE, INC. Therapy focus – against the odds, cancer vaccines plough on. View Luis Aguilar's business profile as Executive Director, Programs at Candel Therapeutics. Candel Therapeutics is a Needham, Massachusetts based biotechnology company developing its … Last year, Candel Therapeutics (Advantagene) announced that it has completed the enrollment of the "ULYSSES" trial, a Phase II study of ProstAtak for prostate cancer patients choosing Active Surveillance (PrTK04-NCT02768363). The treatment is done together with standard radiation therapy. Last year, Candel Therapeutics (Advantagene) announced that it has completed the enrollment of … Contact Media & Investor Relations Candel Therapeutics 117 Kendrick St, Ste 450 Location: Greater Boston Area, MA. Advantagene, Inc. d.b.a. Founded date unknown. Founders Estuardo Aguilar-Cordova. ... Candel Therapeutics. Join to Connect Candel Therapeutics ... Advantagene 2016 - Present 4 years. Claim. The treatment is done together with standard radiation therapy. WARRANT TO PURCHASE COMMON STOCK filed by Candel Therapeutics, Inc. on July 16th, 2021 Last year, Candel Therapeutics (Advantagene) announced that it has completed the enrollment of the "ULYSSES" trial, a Phase II study of ProstAtak for prostate cancer patients choosing Active Surveillance (PrTK04- … AGC Biologics SpA. rQNestin 34.5, a genetically modified oncolytic herpes simplex virus type 1 (HSV1) engineered for enhanced potency, is being developed by Advantagene and Candel rQNestin 34.5 - AdisInsight Either you have JavaScript disabled or your browser does not support Javascript . Candel Therapeutics, Needham, Massachusetts. February 27, 2017. Candel Therapeutics, Inc. ClinicalTrials.gov Identifier: NCT01436968 Other Study ID Numbers: PrTK03 : First Posted: September 20, 2011 Key Record Dates: Last Update Posted: July 9, 2021 Last Verified: July 2021 From 1980-84 he was head of the biochemistry division at the National Institute of Medical Research, Mill Hill, London. Dr. Aguilar-Cordova is the co-founder of Advantagene, Inc. and has been the company's chairman and CEO since 2002. Salaries, reviews, and more - all posted by employees working at Candel Therapeutics. Director, Information Technology. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. WARRANT TO PURCHASE COMMON STOCK filed by Candel Therapeutics, Inc. on July 16th, 2021 The treatment is done together with standard radiation therapy. Phone Number 6179165445. Amendment to Termination Date. It develops Gene Mediated Cytotoxic Immunotherapy (GMCI), a platform technology designed to stimulate a patient’s immune system to naturally fight against cancer. Candel Therapeutics, Inc. ClinicalTrials.gov Identifier: NCT02768363 Other Study ID Numbers: PrTK04 : First Posted: May 11, 2016 Key Record Dates: Last Update Posted: April 28, 2021 Last Verified: April 2021 Individual Participant Data (IPD) Sharing Statement: Plan to Share IPD: No ... Candel Therapeutics. Biliary Tract Cancers (BTC) Market Size Anticipated to Soar During the Forecast Period 2021-30 at a CAGR of 11.69% in the 7MM, Projects DelveInsight PR Newswire LAS VEGAS, May 3, … Advantagene, d.b.a. and the oncolytic rQNestin34.5 platforms for the treatment of solid tumors. Advantagene, also known as Candel Therapeutics, has reached its patient enrollment goal in an ongoing Phase 2 trial testing the effectiveness of ProstAtak, the company’s prostate cancer vaccine, among men with localized prostate cancer who chose to remain on active surveillance.. ProstAtack is a gene-mediated cytotoxic immunotherapy (GMCI). About Candel Therapeutics Candel Therapeutics is a Needham, Massachusetts based biotechnology company developing its proprietary immuno-oncology platforms, including its Gene Mediated Cytotoxic Immunotherapy (GMCI™) and proprietary HSV based platform, for the treatment of solid tumors and associated neurological pathologies. About Candel Therapeutics Advantagene, Inc. d.b.a. Contact Email [email protected]. Candel Therapeutics. Candel said … Listing a study does not mean it has been evaluated by the U.S. Federal Government. Private Company. Private Company. Candel Therapeutics, a company developing proprietary immuno-oncology platforms, closed a $22.5m Series C financing Frequently Asked Questions For Institutional Investors Sage Therapeutics (2) Sirtsei Pharmaceuticals, Inc. (2) Sunovion (2) Zoll Medical Corporation (2) ACADIA Pharmaceuticals Inc. (1) AbbVie (1) Advantagene, Inc. d.b.a. Candel said … The "Outlook for Viral Vector Contract Manufacturing - Gene Therapies, Cell Therapies, and COVID-19 Vaccines" report has been added to ResearchAndMarkets.com's offering.. Candel Therapeutics Paul-Peter Tak, M.D., Ph.D. joins as president and chief executive officer.. Tak takes the reins at Candel after a stint at Flagship Pioneering, where he … The treatment is done together with standard radiation therapy. Last year, Candel Therapeutics (Advantagene) announced that it has completed the enrollment of the "ULYSSES" trial, a Phase II study of ProstAtak for prostate cancer patients choosing Active Surveillance (PrTK04- … CE Disclosures and Faculty Information. . The treatment is done together with standard radiation therapy. Dr. Aguilar-Cordova is the co-founder of Advantagene, Inc. and has been the company's chairman and CEO since 2002. Candel Therapeutics, an Auburndale, MA-based company developing proprietary immuno-oncology platforms, closed a $22.5m Series C financing. Prostate Cancer Market has several treatment options available to treat this condition in the 7MM, such as Active surveillance, Radiation …